Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Landoni, 2018, Treating hematological malignancies with cell therapy: where are we now?, Expert Opin Biol Ther, 18, 65, 10.1080/14712598.2018.1384810 Li, 2016, Adoptive therapy with CAR redirected T cells for hematological malignancies, Sci China Life Sci, 59, 370, 10.1007/s11427-016-5036-3 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Zhang, 2018, Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors, Mol Cancer, 17, 7, 10.1186/s12943-018-0759-3 Gauthier, 2017, Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives, Curr Res Transl Med, 65, 93, 10.1016/j.retram.2017.08.003 Geyer, 2016, Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells, Cytotherapy, 18, 1393, 10.1016/j.jcyt.2016.07.003 Oluwole, 2016, At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies, J Leukoc Biol, 100, 1265, 10.1189/jlb.5BT1115-524R Zhang, 2016, Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors, Sci China Life Sci, 59, 340, 10.1007/s11427-016-5027-4 Newick, 2017, CAR T cell therapy for solid tumors, Annu Rev Med, 68, 139, 10.1146/annurev-med-062315-120245 Mirzaei, 2017, Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications, Front Immunol, 8, 1850, 10.3389/fimmu.2017.01850 US Department of Health and Human Services, 2001, Guidance for human somatic cell therapy and gene therapy, Hum Gene Ther, 12, 303, 10.1089/10430340150218431 European Medicines Agency, 2010 European Medicines Agency, 2007 China Food and Drug Administration, 2003 China Food and Drug Administration, 2017 Petricciani, 2017, Scientific considerations for the regulatory evaluation of cell therapy products, Biologicals, 50, 20, 10.1016/j.biologicals.2017.08.011 Plavsic, 1998, Q5D: derivation and characterization of cell substrates used for production of biotechnological/biological products, 375 World Health Organization, 2010 The United States Pharmacopeial Convention, 2012, Ancillary materials for cell, gene and tissue engineered products, 6850 Armstrong, 2016, Advances in assay technologies for CAR T-cell therapies, BioPharm Int, 28, 32 Piscopo NJ, Mueller KP, Das A, Hematti P, Murphy WL, Palecek SP, et al. Bioengineering solutions for manufacturing challenges in CAR T cells.Biotechnol J. Epub 2017 Sep 18. Gee, 2015, Manufacturing genetically modified T cells for clinical trials, Cancer Gene Ther, 22, 67, 10.1038/cgt.2014.71 Hollyman, 2009, Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy, J Immunother, 32, 169, 10.1097/CJI.0b013e318194a6e8 Tumaini, 2013, Simplified process for the production of anti-CD19-CAR-engineered T cells, Cytotherapy, 15, 1406, 10.1016/j.jcyt.2013.06.003 Center for Drug Evaluation of the China Food and Drug Administration, 2018 National Institutes for Food and Drug Control, 2018 Siegler, 2018, Preclinical models in chimeric antigen receptor-engineered T-cell therapy, Hum Gene Ther, 29, 534, 10.1089/hum.2017.243 Hudecek, 2015, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol Res, 3, 125, 10.1158/2326-6066.CIR-14-0127 Cooper, 2005, Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1, Blood, 105, 1622, 10.1182/blood-2004-03-1208 Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002 Hudecek, 2013, Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells, Clin Cancer Res, 19, 3153, 10.1158/1078-0432.CCR-13-0330 Tammana, 2010, 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies, Hum Gene Ther, 21, 75, 10.1089/hum.2009.122 Fesnak, 2016, Engineered T cells: the promise and challenges of cancer immunotherapy, Nat Rev Cancer, 16, 566, 10.1038/nrc.2016.97 Jackson, 2016, Driving CAR T-cells forward, Nat Rev Clin Oncol, 13, 370, 10.1038/nrclinonc.2016.36 Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov, 3, 388, 10.1158/2159-8290.CD-12-0548 Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247 Ghosh, 2017, Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity, Nat Med, 23, 242, 10.1038/nm.4258 Liu, 2016, Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy, Nat Biotechnol, 34, 430, 10.1038/nbt.3461 Almåsbak, 2015, Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model, Gene Ther, 22, 391, 10.1038/gt.2015.4 Li, 2005, Study of requirements for quality control of recombinant adenovirus-mediated human endostatin, Chin J Cancer Biother, 12, 138 Li, 2008, Study on quality control methods and requirements of recombinant plasmid DNA expressing human plasminogen kringle 5, Chin J Pharm Anal, 28, 661 Fu, 2015, Analysis on quality of recombinant adeno-associated virus 2 encoding tumor necrosis factor-related apoptosis-induced ligand, Chin J Biologicals, 28, 501 Wang, 2015, Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies, Cancer Gene Ther, 22, 85, 10.1038/cgt.2014.81 Singh, 2013, Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells, PLoS ONE, 8, 10.1371/journal.pone.0064138 Center for Biologics Evaluation and Research [CBER] (United States), 2001, Guidance for industry: supplemental guidance on testing for replication-competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors, Hum Gene Ther, 12, 315, 10.1089/10430340150218440 Cornetta, 2011, Replication-competent lentivirus analysis of clinical grade vector products, Mol Ther, 19, 557, 10.1038/mt.2010.278 Long, 1998, Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells, Hum Gene Ther, 9, 1165, 10.1089/hum.1998.9.8-1165 Martineau, 1997, Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus, Hum Gene Ther, 8, 1231, 10.1089/hum.1997.8.10-1231 Printz, 1995, Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays, Gene Ther, 2, 143 Forestell, 1996, Improved detection of replication-competent retrovirus, J Virol Methods, 60, 171, 10.1016/0166-0934(96)02052-6 Miller, 1996, A novel murine retrovirus identified during testing for helper virus in human gene transfer trials, J Virol, 70, 1804, 10.1128/JVI.70.3.1804-1809.1996 Escarpe, 2003, Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations, Mol Ther, 8, 332, 10.1016/S1525-0016(03)00167-9 Farley, 2015, Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors, Mol Ther Methods Clin Dev, 2, 15017, 10.1038/mtm.2015.17 Corre, 2016, “RCL-pooling assay”: a simplified method for the detection of replication-competent lentiviruses in vector batches using sequential pooling, Hum Gene Ther, 27, 202, 10.1089/hum.2015.166 Bear, 2012, Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?, Mol Ther, 20, 246, 10.1038/mt.2011.288 McGarrity, 2013, Patient monitoring and follow-up in lentiviral clinical trials, J Gene Med, 15, 78, 10.1002/jgm.2691 Marcucci, 2018, Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients, Mol Ther, 26, 269, 10.1016/j.ymthe.2017.10.012 Cornetta, 2018, Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products, Mol Ther, 26, 280, 10.1016/j.ymthe.2017.09.008 Hocquet, 2014, Validation of an automated blood culture system for sterility testing of cell therapy products, Cytotherapy, 16, 692, 10.1016/j.jcyt.2013.09.005 Volokhov, 2011, Mycoplasma testing of cell substrates and biologics: review of alternative non-microbiological techniques, Mol Cell Probes, 25, 69, 10.1016/j.mcp.2011.01.002 Uphoff, 2014, Eradication of mycoplasma contaminations from cell cultures, Curr Protoc Mol Biol, 106, 10.1002/0471142727.mb2805s106 Skrdlant, 2017, Detection of replication competent lentivirus using a qPCR assay for VSV-G, Mol Ther Methods Clin Dev, 8, 1, 10.1016/j.omtm.2017.09.001 Mallet, 2014, Need for new technologies for detection of adventitious agents in vaccines and other biological products, PDA J Pharm Sci Technol, 68, 556, 10.5731/pdajpst.2014.01012 Mee, 2016, Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing, Vaccine, 34, 2035, 10.1016/j.vaccine.2015.12.020 McClenahan, 2014, Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing, Vaccine, 32, 7115, 10.1016/j.vaccine.2014.10.022 US Department of Health and Human Services, 2011 Bravery, 2013, Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry, Cytotherapy, 15, 9, 10.1016/j.jcyt.2012.10.008 Xiong, 2018, Immunological synapse predicts effectiveness of chimeric antigen receptor cells, Mol Ther, 26, 963, 10.1016/j.ymthe.2018.01.020 Levine, 2016, Global manufacturing of CAR T cell therapy, Mol Ther Methods Clin Dev, 4, 92, 10.1016/j.omtm.2016.12.006 Revzin, 2012, Biosensors for immune cell analysis—a perspective, Biomicrofluidics, 6, 10.1063/1.4706845 Baradez, 2011, The use of multidimensional image-based analysis to accurately monitor cell growth in 3D bioreactor culture, PLoS ONE, 6, 10.1371/journal.pone.0026104 Aghaeepour, 2013, Critical assessment of automated flow cytometry data analysis techniques, Nat Methods, 10, 228, 10.1038/nmeth.2365 Kuystermans, 2016, Online flow cytometry for monitoring apoptosis in mammalian cell cultures as an application for process analytical technology, Cytotechnology, 68, 399, 10.1007/s10616-014-9791-3 Locasale, 2011, Metabolic flux and the regulation of mammalian cell growth, Cell Metab, 14, 443, 10.1016/j.cmet.2011.07.014 Lipsitz, 2016, Quality cell therapy manufacturing by design, Nat Biotechnol, 34, 393, 10.1038/nbt.3525 Fesnak, 2017, Considerations in T cell therapy product development for B cell leukemia and lymphoma immunotherapy, Curr Hematol Malig Rep, 12, 335, 10.1007/s11899-017-0395-9 Lock, 2017, Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use, Hum Gene Ther, 28, 914, 10.1089/hum.2017.111 Zhao, 2017, Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products, Hum Gene Ther Methods, 28, 205, 10.1089/hgtb.2017.078 Wang, 2016, Construction and application of humanized immune system mice, Chin J Immunol, 32, 289 Siegler, 2018, Preclinical models in chimeric antigen receptor-engineered T cell therapy, Hum Gene Ther, 29, 534, 10.1089/hum.2017.243 Cheadle, 2010, Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells, J Immunol, 184, 1885, 10.4049/jimmunol.0901440 Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol Ther Oncolytics, 3, 16011, 10.1038/mto.2016.11